Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more
more details :

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Wednesday, August 26, 2009

Pubmed paper 2009 : Actions of Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3

Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3

Regular readers will know that FMO3 enzyme is always of special interest to the blog. This is the latest pubmed paper about the enzyme, albeit only in a limited way.

The testers were testing the phase1 xenobiotic metabolizing enzymes to see how they are affected by natural medicines used by Cree Indians in Canada.Normally when researchers check reactions in phase 1 xenobiotic metabolizing enzymes, they only check the Cytochrome P450 super-family, even though the FMO family come into this category. This is probably because at the moment the FMO enzymes are perceived as unimportant. So it was good to see FMO3 tested in this test as well.

Probably the main reason for interest in these enzymes is that drugs are metabolized by them, and they can also have an inhibitive or inducing effect on the enzymes. Probably one priority to pharmaceutical industry testers is the thought of lawsuits. These enzymes have only been properly known about for about 50 years, and so a lot has still to be learnt about them, especially the FMO family. Presumably the tests were done 'in vitro' at a lab, rather than 'in vivo'.

The 'textbook' definition of FMO enzymes will say it can neither be induced or inhibited, even though those using the same definition have found a compound in cruciferous vegetables to be very inhibitive. In this study, FMO3 seemed to be 'middling' inhibited by the plant extracts used. However, it's not known how conclusive such studies can be, since often there are other conflicting papers published. Perhaps the 'behaviour' of a xenobiotic metabolizing enzyme isn't accepted until a definite trend in papers is seen.

Herbs and spices are of special interest in FMO3 because most are likely FMO3 'substrates' and also may have an inhibitive/inducing effect (currently unknown). This may explain why when taking herbs/spices/medicines, some may feel 'strange' and perhaps get pain around the liver (since the liver is the most prominent place where such enzymes are based).

body odor

phase1 : modify a compound
phase2 : add a molecule to a compound; conjugate

These enzymes deal with internally produced compounds (neurotransmitters, hormones etc) as well as external compounds (from diet and environment etc)

The most abundant area for these enzymes is the liver, but they are everywhere.


Post a Comment